ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Roche and the Medicines Patent Pool have inked a supply agreement for Valcyte, an oral treatment for cytomegalovirus, a viral infection that can cause blindness and affects roughly one in 10 people living with HIV in low- and middle-income countries. Medicines Patent Pool is a United Nations-backed mechanism that lowers HIV drug prices by making patent licenses available to generic drug firms. Under the pact, Valcyte will be available at up to a 90% discount in 138 developing and emerging countries, the partners say. As part of the deal, Roche will also provide a license for the HIV medication saquinavir if the need arises.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter